Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
PaperCitations, authors & open-access status
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 62 citations, 2023 year and closed oa status.
62
Citations
2023
Year
closed
OA Status